The present disclosure relates generally to site markers for breast biopsy procedures.
In the diagnosis and treatment of breast cancer, it is often necessary to perform a biopsy to remove tissue samples from a suspicious mass. The suspicious mass is typically discovered during a preliminary examination involving visual examination, palpation, X-ray, magnetic resonance imaging (MRI), ultrasound imaging or other detection means.
When a suspicious mass is detected, a sample is taken by biopsy, and then tested to determine whether the mass is malignant or benign. This biopsy procedure can be performed by an open surgical technique, or through the use of a specialized biopsy instrument. To minimize surgical intrusion, a small specialized instrument such as a biopsy needle is inserted in the breast while the position of the needle is monitored using fluoroscopy, ultrasonic imaging, X-rays, MRI or other suitable imaging techniques.
In one biopsy procedure, referred to as stereotactic needle biopsy, the patient lies on a special biopsy table with her breast compressed between the plates of a mammography apparatus and two separate X-rays are taken from two different points of reference. A computer then calculates the exact position of the mass or lesion within the breast. The coordinates of the lesion are then programmed into a mechanical stereotactic apparatus which advances the biopsy needle into the lesion with precision. At least five biopsy samples are usually taken from locations around the lesion and one from the center of the lesion.
Regardless of the method or instrument used to perform the biopsy, subsequent examination of the surgical site may be necessary, either in a follow up examination or for treatment of a cancerous lesion. Treatment often includes a mastectomy, lumpectomy, radiation therapy, or chemotherapy procedure that requires the surgeon or radiologist to direct surgical or radiation treatment to the precise location of the lesion. Because this treatment might extend over days or weeks after the biopsy procedure, and the original features of the tissue may have been removed or altered by the biopsy, it is desirable to insert a site marker into the surgical cavity to serve as a landmark for future identification of the location of the lesion.
Known biopsy site markers have been found to have disadvantages in that the site markers are not visible under all available modalities. Moreover, because of this problem, when cancer is found at a biopsy site that has been previously marked with a site marker, due to the poor visibility of the biopsy site marker under ultrasound or other visualization modalities, the patient must undergo an additional procedure that places an additional device within the biopsy site to enable the surgeon to find the biopsy site in subsequent procedures. One known technique has been to place a breast lesion localization wire at the biopsy site. The localization wire is typically placed at the biopsy site via mammography and/or ultrasound.
Another issue that arises with site markers is migration. When the site markers are typically deployed to the biopsy site, the breast is still under compression. However, when the breast is released from compression, the site marker may migrate within the site or even out of the site through a needle tract created by the biopsy device, thereby preventing a surgeon or radiologist from easily locating the precise location of the lesion or biopsied area.
Accordingly, there is a need for site markers made from biocompatible materials that are visible under various modes of imaging to reduce the number of procedures that patients must undergo in detection and treatment of cancer. There is also a need to limit migration of a site marker when the site marker is placed in a biopsy site.
A site marker is disclosed comprising a body portion and a marker element. The body portion is constructed of a bioabsorbable material and defines at least one cavity therein. The marker element is captured within one of the cavities. The marker element is constructed of a material that may be imaged under at least one imaging modality.
These and other features and advantages of the invention will be apparent from the following detailed description and the appended claims, taken in conjunction with the accompanying drawings, in which:
Referring initially to
In another embodiment, the capsule 24 is constructed of a material that is designed to resonate at a predetermined ultrasound frequency. The resonance will be visible under one or more imaging modalities. In the event that the capsule 24 needs to resonate at more than one frequency, a resonant beam 32, as shown in
Referring to
In one embodiment, body portion 36 is constructed of a bioabsorbable material such as polyglycolic acid (PGA), polylactic acid (PLA), hydrogel, collegen-based material or any other suitable material. The bioabsorbable material may be woven into a flexible mesh that has openings formed therein that are sized so as to be smaller than permanent marker 42 such that permanent marker 42 cannot escape body portion 36. After installation in a biopsy cavity, over a predetermined time period, such as, for example, a few weeks to several months, body portion 36 is absorbed by the body, such that only permanent marker 42 remains within the body at the biopsy cavity. Because permanent marker 42 is captured within body portion 36 prior to absorption thereof by the body, permanent marker 42 is restricted from migrating from within the biopsy cavity. Indeed, movement of permanent marker 42 is limited to the internal cavity defined by body portion 36. This insures that permanent marker 42 remains within the biopsy cavity to permit follow-up imaging of the biopsy site.
In one embodiment, prior to deployment into the biopsy site by a suitable deployment mechanism, site marker 34, and more specifically, body portion 36, is formed in a first pre-deployment configuration (as shown in
In another embodiment, as shown in
In another embodiment, as shown in
Site marker 50 expands from a first pre-deployment configuration (shown in
In one embodiment, the material may from which site marker 50 is constructed is a shape memory material that will spring into the second post deployment configuration upon release from a deployment device into a biopsy cavity. In accordance with this embodiment, the site marker is designed to have a predetermined shape and then compressed into the first pre-deployment configuration. The site marker is then retained in the first pre-deployment configuration and may be loaded into a deployment device. It should be noted that the site marker may be stored in the deployment device in the first pre-deployment configuration for an extended period of time.
Once released from the deployment device and into the biopsy cavity, the site marker automatically springs into the second post-deployment configuration having a predetermined size and shape such that the site marker is easily visible under various imaging modalities.
In another embodiment, site marker 50 is constructed of a temperature dependent material. In accordance with this embodiment, the site marker does not expand from the first pre-deployment configuration into the second post-deployment configuration until heat is applied to the site marker 50. Deploying the site marker 50 into a biopsy cavity provides a sufficient level of heat generated from the body to enable site marker 50 to automatically expand into the second post-deployment configuration after deployment.
Another embodiment of a site marker 52 is shown in
While body portion 54 is illustrated as a mesh material having small openings therethrough, it is understood that the embodiment is not limited to use of a mesh material. Indeed, the material need not have any small openings therein. Further, in the embodiment shown in
As mentioned above, the permanent marker 58 may be any shape. To facilitate its recognition, permanent marker 58 may (but is not required to) have a predefined shape, such as the Venus symbol as shown in
Another embodiment of a site marker 68 is shown in
While the embodiment shown in
While body portion 70 is illustrated as a mesh material having small openings therethrough, it is understood that the embodiment is not limited to use of a mesh material. Indeed, the material need not have any small openings therein. Further, in the embodiment shown in
Another embodiment of a site marker 78 is illustrated in
Due to the nested configuration of first and second body portions 80 and 82 and permanent marker 92, movement of the permanent marker 92 will is restricted to second cavity 90. Thus, when deployed into a biopsy cavity, migration of the permanent marker 92 will be minimized.
While body portion 70 is illustrated as a mesh material having small openings therethrough, it is understood that the embodiment is not limited to use of a mesh material. Indeed, the material need not have any small openings therein. Further, in the embodiment shown in
In one embodiment, cannula body 96 is illustrated as a mesh having a plurality of openings that are substantially smaller than the size of the permanent marker 100. Thus, permanent marker 100 is prevented from escaping from the chamber of the cannula body 96 when the ends 98 are sealed. It is also understood, however, that the cannula body 96 may be constructed of a bioabsorbable material that does not have any openings without departing from the disclosure.
While the present invention has been particularly shown and described with reference to the foregoing preferred embodiments, it should be understood by those skilled in the art that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention without departing from the spirit and scope of the invention as defined in the following claims. It is intended that the following claims define the scope of the invention embodiments within the scope of these claims and their equivalents be covered thereby. This description of the invention should be understood to include all novel and non-obvious combinations of elements described herein, and claims may be presented in this or a later application to any novel and non-obvious combination of these elements. The foregoing embodiment is illustrative, and no single feature or element is essential to all possible combinations that may be claimed in this or a later application.
This application is a Continuation-in-part of U.S. application Ser. No. 11/242,334, filed Oct. 3, 2005, which application is a continuation-in-part of U.S. Ser. No. 10/964,087, entitled SITE MARKER VISIBLE UNDER MULTIPLE MODALITIES, filed Oct. 13, 2004, both applications of which are incorporated herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4774957 | Nambu et al. | Oct 1988 | A |
4991579 | Allen | Feb 1991 | A |
5010145 | Ikada et al. | Apr 1991 | A |
5016639 | Allen | May 1991 | A |
5097839 | Allen | Mar 1992 | A |
5104539 | Anderson et al. | Apr 1992 | A |
5211164 | Allen | May 1993 | A |
5218964 | Sepponen | Jun 1993 | A |
5368030 | Zinreich et al. | Nov 1994 | A |
5397329 | Allen | Mar 1995 | A |
5427099 | Adams | Jun 1995 | A |
5469847 | Zinreich et al. | Nov 1995 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5730130 | Fitzpatrick et al. | Mar 1998 | A |
5769789 | Wang et al. | Jun 1998 | A |
5782764 | Werne | Jul 1998 | A |
5902310 | Foerster et al. | May 1999 | A |
5941890 | Voegele et al. | Aug 1999 | A |
5961455 | Daum et al. | Oct 1999 | A |
6011987 | Barnett | Jan 2000 | A |
6015844 | Harvey et al. | Jan 2000 | A |
6016439 | Acker | Jan 2000 | A |
6056700 | Burney et al. | May 2000 | A |
6057700 | Crispell | May 2000 | A |
6173715 | Sinanan et al. | Jan 2001 | B1 |
6228055 | Foerster et al. | May 2001 | B1 |
6231834 | Unger et al. | May 2001 | B1 |
6261302 | Voegele et al. | Jul 2001 | B1 |
6270464 | Fulton, III et al. | Aug 2001 | B1 |
6280385 | Melzer et al. | Aug 2001 | B1 |
6333971 | McCrory et al. | Dec 2001 | B2 |
6347241 | Burbank et al. | Feb 2002 | B2 |
6350244 | Fisher | Feb 2002 | B1 |
6356782 | Sirimanne et al. | Mar 2002 | B1 |
6371904 | Sirimanne et al. | Apr 2002 | B1 |
6379379 | Wang | Apr 2002 | B1 |
6427081 | Burbank et al. | Jul 2002 | B1 |
6466813 | Shukla et al. | Oct 2002 | B1 |
6544185 | Montegrande | Apr 2003 | B2 |
6567687 | Front et al. | May 2003 | B2 |
6628982 | Thomas et al. | Sep 2003 | B1 |
6640127 | Kosaka et al. | Oct 2003 | B1 |
6687533 | Hirano et al. | Feb 2004 | B1 |
6699205 | Fulton, III et al. | Mar 2004 | B2 |
6725083 | Burbank et al. | Apr 2004 | B1 |
6766186 | Hoyns et al. | Jul 2004 | B1 |
6862470 | Burbank et al. | Mar 2005 | B2 |
7229417 | Foerster et al. | Jun 2007 | B2 |
7611462 | Vortman et al. | Nov 2009 | B2 |
7625397 | Foerster et al. | Dec 2009 | B2 |
20010049549 | Boylan et al. | Dec 2001 | A1 |
20020035324 | Sirimanne et al. | Mar 2002 | A1 |
20020082517 | Klein | Jun 2002 | A1 |
20020156372 | Skakoon et al. | Oct 2002 | A1 |
20020161298 | Burbank et al. | Oct 2002 | A1 |
20020188196 | Burbank et al. | Dec 2002 | A1 |
20020193815 | Foerster et al. | Dec 2002 | A1 |
20030004563 | Jackson et al. | Jan 2003 | A1 |
20030097059 | Sorrell et al. | May 2003 | A1 |
20030139669 | Montegrande | Jul 2003 | A1 |
20030199785 | Hibner et al. | Oct 2003 | A1 |
20040030237 | Lee et al. | Feb 2004 | A1 |
20040030262 | Fisher et al. | Feb 2004 | A1 |
20040049224 | Buehlmann et al. | Mar 2004 | A1 |
20040093069 | Priewe et al. | May 2004 | A1 |
20040097981 | Selis | May 2004 | A1 |
20040105890 | Klein et al. | Jun 2004 | A1 |
20040110059 | Onishi et al. | Jun 2004 | A1 |
20040116802 | Jessop et al. | Jun 2004 | A1 |
20040116805 | Chesbrough et al. | Jun 2004 | A1 |
20040116806 | Burbank et al. | Jun 2004 | A1 |
20040138555 | Krag et al. | Jul 2004 | A1 |
20040219186 | Ayres | Nov 2004 | A1 |
20050033157 | Klein et al. | Feb 2005 | A1 |
20050063908 | Burbank et al. | Mar 2005 | A1 |
20050277871 | Selis | Dec 2005 | A1 |
20050288764 | Snow et al. | Dec 2005 | A1 |
20060009712 | Van Bladel et al. | Jan 2006 | A1 |
20060079805 | Miller et al. | Apr 2006 | A1 |
20060173296 | Miller et al. | Aug 2006 | A1 |
20070093726 | Leopold et al. | Apr 2007 | A1 |
20070118176 | Opolski et al. | May 2007 | A1 |
20070167980 | Figulla et al. | Jul 2007 | A1 |
20080058715 | Houser et al. | Mar 2008 | A1 |
20080269603 | Nicoson | Oct 2008 | A1 |
Number | Date | Country |
---|---|---|
1491147 | Dec 2004 | EP |
1579878 | Sep 2005 | EP |
1 602 341 | Dec 2005 | EP |
1 925 266 | May 2008 | EP |
WO-0024332 | May 2000 | WO |
WO-0100101 | Jan 2001 | WO |
WO-0108578 | Feb 2001 | WO |
WO-0230482 | Apr 2002 | WO |
WO-2004012600 | Feb 2004 | WO |
Entry |
---|
Final Office Action dated Feb. 16, 2010 for U.S. Appl. No. 10.964,087. |
Response to Final Office Action dated Feb. 16, 2010 for U.S. Appl. No. 10/964,087. |
ACS Industries, Inc. publication entitled “ImagineKnit, We'll Provide It!” Sep. 2003. |
Alatassi, Houda et al., “Breast Biopsy Marker Masquerading as a Mass Lesion”, The Breast Journal, vol. 11, Nov. 6, 2006, pp. 504-505. |
Wahner-Roedler, Dietlind L., “Vacuum-Assisted Breast Biopsy Device (Mammotome) Malfunction Simulating Microcalcifications”, The Breast Journal, vol. 11, Nov. 6, 2005, pp. 474-475. |
PCT International Search Report for PCT/US2005/034809. |
PCT International Search Report #PCT/1B2006/053546. |
Office Action dated Aug. 4, 2009 for U.S. Appl. No. 10/964,087. |
Response to Office Action dated Aug. 4, 2009 for U.S. Appl. No. 10/964,087. |
PCT International Search Report for PCT/US2009/046200 dated Oct. 5, 2009. |
Non-Final Office Action dated Jun. 8, 2010 for U.S. Appl. No. 10/964,087. |
Amendment After Final Office Action filed with RCE in response to Advisory Action dated May 6, 2010 for U.S. Appl. No. 10/964,087. |
Non-Final Office Action dated Aug. 4, 2010 for U.S. Appl. No. 12/269,501. |
Non-Final Office Action dated Jun. 28, 2010 for U.S. Appl. No. 11/242,334. |
Response to Non-Final Office Action dated Jun. 8, 2010 for U.S. Appl. No. 10/964,087. |
Response to Non-Final Office Action dated Jun. 28, 2010 for U.S. Appl. No. 11/242,334. |
Response to Non-Final Office Action dated Aug. 4, 2010 for U.S. Appl. No. 12/269,501. |
Annex to the European Search Report dated Aug. 18, 2010 for EP07254526. |
Non-Final Office Action dated Dec. 8, 2010 in U.S. Appl. No. 10/964,087. |
Final Office Action dated Jan. 4, 2011 for U.S. Appl. No. 11/242,334. |
Non-Final Office Action dated Dec. 27, 2010 for U.S. Appl. No. 11/561,919. |
Non-Final Office Action dated Feb. 17, 2011 for U.S. Appl. No. 12/269,501. |
Response to Non-Final Office Action dated Dec. 8, 2010 for U.S. Appl. No. 10/964,087. |
Response to Non-Final Office Action dated Dec. 27, 2010 for U.S. Appl. No. 11/561,919. |
Response to Final Office Action dated Jan. 4, 2011 for U.S. Appl. No. 11/242,334. |
Final Office Action dated May 19, 2011 for U.S. Appl. No. 10/964,087. |
Notice of Allowance dated Jun. 10, 2011 for U.S. Appl. No. 11/561,919. |
Non-Final Office Action dated Jul. 6, 2011 for U.S. Appl. No. 11/242,334. |
Final Office Action dated Aug. 3, 2011 for U.S. Appl. No. 12/269,501. |
Response to Non-Final Office Action dated Jul. 6, 2011 for U.S. Appl. No. 11/242,334. |
Number | Date | Country | |
---|---|---|---|
20080269603 A1 | Oct 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11242334 | Oct 2005 | US |
Child | 12133212 | US | |
Parent | 10964087 | Oct 2004 | US |
Child | 11242334 | US |